RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Carfilzomib may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells by blocking
blood flow to the tumor. Giving combination chemotherapy together with carfilzomib and
thalidomide may kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of carfilzomib when
given together with cyclophosphamide, thalidomide, and dexamethasone in treating patients
with newly diagnosed active multiple myeloma.